Table 2.

Risk-stratified outcomes after NMA haplo BMT based on refined DRI

Variable: refined DRI group	Probability (95% CI)				P*
	All patients (n = 372)	Low risk (n = 71)	Intermediate risk (n = 241)	High/very high risk (n = 60)
NRM (CuI)					.60
Day 180	0.08 (0.05-0.11)	0.03 (0-0.07)	0.10 (0.06-0.14)	0.05 (0-0.11)
1 y	0.11 (0.08-0.14)	0.10 (0.03-0.17)	0.13 (0.08-0.17)	0.05 (0-0.11)
Relapse (CuI)					<.0001
1 y	0.37 (0.32-0.42)	0.17 (0.08-0.26)	0.38 (0.32-0.44)	0.58 (0.46-0.71)
3 y	0.46 (0.41-0.51)	0.20 (0.11-0.30)	0.48 (0.41-0.54)	0.67 (0.55-0.80)
PFS					<.0001
1 y	0.52 (0.47-0.57)	0.73 (0.63-0.84)	0.50 (0.44-0.56)	0.37 (0.26-0.51)
3 y	0.40 (0.35-0.45)	0.65 (0.55-0.78)	0.37 (0.31-0.44)	0.22 (0.14-0.36)
DFS					<.0001
1 y	0.51 (0.46-0.57)	0.70 (0.60-0.82)	0.50 (0.44-0.56)	0.35 (0.25-0.49)
3 y	0.61 (0.57-0.66)	0.64 (0.54-0.76)	0.37 (0.31-0.44)	0.22 (0.14-0.36)
OS					.0001
1 y	0.68 (0.63-0.73)	0.81 (0.73-0.91)	0.67 (0.61-0.73)	0.55 (0.44-0.69)
3 y	0.50 (0.45-0.56)	0.71 (0.60-0.82)	0.48 (0.42-0.55)	0.35 (0.24-0.49)

DFS, disease-free survival.

^*P for differences between refined DRI risk groups, with stratification by BMT year.